US FDA AWARDS ISRAEL'S TEVA APPROVAL FOR ANTIFUNGAL PRODUCT

Israel-based generics major Teva has announced that the abbreviated new drug application for its injectable antifungal Fluconazole has received final US FDA approval.

The treatment is a generic version of Pfizer's Diflucan, and is to be available as a 2 mg/mL dose, in 200- and 400-mg bags. Teva, which has not announced a launch date for the product, claims that the drug's branded and generic sales total some US$167mn per year.